📊 PRO: This Week in Visuals
AMZN LLY NVO MRK DIS PEP PLTR LRLCY QCOM AMD ARM AMGN PFE UBER FI SPOT PYPL RACE CMG FTNT MDLZ GSK RBLX F YUM TTWO EA HSY PINS EXPE AFRM SNAP ALGN NYT MTCH PTON
Welcome to the Saturday PRO edition of How They Make Money.
Over 180,000 subscribers turn to us for business and investment insights.
In case you missed it:
📧 Free members get our Friday articles and sneak peeks.
💌 Premium members receive monthly reports with 200+ companies visualized, one extra weekly article, and access to our archive.
💼 PRO members enjoy everything in Premium, plus our Saturday timely coverage of the most important earnings of the past week.
Today at a glance:
☁️ Amazon: Capacity Limits
💊 Eli Lilly: Supply Scaling With Demand
🇩🇰 Novo Nordisk: Strong GLP-1 Growth
🦠 Merck: Gardasil Pause
🏰 Disney: Box Office Boost
🥤 PepsiCo: Consumer Shifts
🕵️ Palantir: Astounding AI Demand
💄 L'Oréal: China Weighs on Growth
📲 Qualcomm: Strong Finish
⚙️ AMD: High Expectations
📱 ARM: AI Growth Continues
🧬 Amgen: Obesity Pipeline in Focus
💉 Pfizer: Cost Cuts & Covid Stability
🚖 Uber: Strong Growth, Muted Outlook
💳 Fiserv: Clover Powers Growth
🎧 Spotify: First Annual Profit
💳 Paypal: Checkout & Venmo Focus
🏎️ Ferrari: Accelerating Profitability
🌯 Chipotle: Expansion Continues
🔒 Fortinet: Firewall Refresh Ahead
🍪 Mondelez: Cocoa Costs Bite
💉 GSK: Raised 2031 Outlook
👾 Roblox: Bookings Growth Slows
🚙 Ford: Cost Cuts Ahead
🌮 YUM Brands: Taco Bell Leads Again
🎮 Take-Two: Big Titles Ahead
⚽ Electronic Arts: Sports Slump Hits Hard
🍫 Hershey: Commodity Hedging
📌 Pinterest: First Billion-Dollar Quarter
✈️ Expedia: Holiday Surge
🌈 Affirm: Profit Ahead
👻 Snap: Nearly Breakeven
🦷 Align: Soft Guidance
🗞️ New York Times: Outlook Comes Short
🔥 Match Group: New CEO, Same Challenges
🚲 Peloton: Subscribers Decline
1. ☁️ Amazon: Capacity Limits
Amazon saw revenue grow 10% Y/Y to $187.8 billion ($0.5 billion beat), and EPS was $1.86 ($0.38 beat). Operating income surged 61% to a record $21.2 billion, driven by efficiency gains and cloud profits. AWS revenue grew 19% to $28.8 billion, maintaining steady growth but facing capacity constraints due to chip supply and power availability, which may ease in the second half of 2025.
Despite strong results, Q1 guidance disappointed, with revenue projected at $151 to $155.5 billion( $158.6 billion expected) and operating income guidance of $14 to $18 billion ($18.4 billion expected). Management cited foreign exchange headwinds ($2.1 billion impact), a leap-year comparison, and infrastructure investments as key factors.
Amazon is set to invest over $100 billion in 2025 primarily in AI, custom chips, and data centers to meet soaring demand. While CEO Andy Jassy described Amazon as an “AI supermarket,” near-term concerns about cloud growth and margins weighed on investor sentiment. However, Amazon has the balance sheet and operating cash flow ($116 billion in FY24) to fund its growth initiatives.
Next week, we’ll dive deeper into the report, visualizing market share shifts in cloud infrastructure and advertising. Stay tuned!
2. 💊 Eli Lilly: Supply Scaling With Demand
Eli Lilly’s revenue surged 45% Y/Y to $13.5 billion ($100 million beat), driven by Mounjaro sales reaching $3.5 billion and Zepbound at $1.9 billion, both in line with pre-announced figures. While sales fell short of original expectations last quarter, FY25 guidance of $58-61 billion (+32% Y/Y) reassured investors. Management emphasized manufacturing expansion, with a 60% increase in GLP-1 supply expected in H1 2025 to support growing demand. The removal of Mounjaro and Zepbound from the FDA’s shortage list will also curb compounded alternatives, further solidifying Lilly’s market position.
With regulatory approvals for Kisunla and Ebglyss, expanded global launches for Mounjaro, and ongoing payer negotiations for Zepbound reimbursement, Lilly continues to strengthen its obesity and diabetes portfolio. Management remains bullish on the long-term growth runway, with further capacity investments needed to meet demand. The next key catalyst will be late-stage data for Orforglipron, Lilly’s oral obesity drug, expected mid-year.